Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07199569 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 744 to confirmed 970
    • Primary and study completion dates: Oct 31, 2026 to Nov 30, 2026
    • Site details revised at 10 of 10 sites
    v4
  2. Site details revised at 9 of 10 sitesv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 10
    • Start date changed from estimate of Oct 31, 2025 to Oct 27, 2025
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Randomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults
Trial Details
NCT Number NCT07199569
Lead Sponsor Bavarian Nordic
Collaborators: ICON plc
Conditions
(from sponsor)		 Monkeypox (Mpox)
Related terms Mpox, Monkeypox
Enrollment 970 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov